Lori Reed
Family · Marietta, GANPI 1811398001
Payments from drug & device makers
Across 556 payments — averaging $190.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$61K
- Actelion Pharmaceuticals US, Inc.$36K
- Merck$5K
- GSK$564
- AstraZeneca$526
- Bayer$511
- plus $3K from 29 others
What the payments were for
- Consulting fees$14,90514%
- Speaking & faculty fees$57,29354%
- Travel & lodging$19,80019%
- Food & beverage$13,92113%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 207 | $60,784 |
| Actelion Pharmaceuticals US, Inc. | 118 | $36,273 |
| Merck | 35 | $4,622 |
| GSK | 40 | $564 |
| AstraZeneca | 22 | $526 |
| Bayer | 18 | $511 |
| Boehringer Ingelheim | 16 | $457 |
| Insmed, Inc. | 18 | $420 |
| Johnson & Johnson | 3 | $247 |
| Grifols USA, LLC | 9 | $207 |
| Jazz Pharmaceuticals Inc. | 8 | $189 |
| Regeneron Healthcare Solutions, Inc. | 8 | $184 |
| Sandoz | 7 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $120 |
| Axsome Therapeutics, Inc. | 5 | $116 |
| Pfizer | 6 | $107 |
| Verona Pharma, Inc. | 4 | $101 |
| Amgen | 5 | $83 |
| Sanofi | 3 | $63 |
| Harmony Biosciences LLC | 2 | $52 |
| Mylan Specialty L.p. | 2 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Novartis | 1 | $28 |
| Noctrix Health, Inc. | 1 | $27 |
| Tactile Systems Technology Inc | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $25 |
| Boston Scientific | 1 | $23 |
| Viatris Specialty LLC | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Gilead | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Resmed Corp | 1 | $13 |
| Inogen, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,107 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 299 | $4,160,378 |
| UptraviSelexipag | 159 | $3,838,302 |
| OpsumitMacitentan | 285 | $3,590,212 |
| Orenitram ErTreprostinil Diolamine | 118 | $1,973,691 |
| LetairisAmbrisentan | 54 | $703,039 |
| Tyvaso DpiTreprostinil | 13 | $318,061 |
| AdcircaTadalafil | 48 | $242,126 |
| Ambrisentan | 61 | $227,125 |
| EliquisApixaban | 99 | $85,091 |
| Tadalafil | 130 | $64,577 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $40,023 |
| Dupixent SyringeDupilumab | 11 | $38,405 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $37,494 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $21,979 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $21,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Bosentan | $36,273 | $7,433,148456 claims |
| BayerAdempas | $511 | $4,160,378299 claims |
| GileadLetairis | $15 | $703,03954 claims |
| United Therapeutics CorporationAdcirca | $60,784 | $242,12648 claims |
| PfizerEliquis | $107 | $85,09199 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $564 | $80,828121 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $526 | $44,30246 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $457 | $23,72447 claims |
| Johnson & JohnsonXarelto | $247 | $19,04230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Marietta
- Allie McAllisterMarietta$299K
- Jennifer MekhoukhMarietta$38K
- Janie DinhMarietta$14K
- Erin EsfahaniMarietta$14K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.